Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hormone Replacement After Brain Injury
NCT01397500Phase 2Terminated
- Sponsor
- Max Planck Institute of Psychiatry
- Start
- Nov 2011
- Primary completion
- Feb 2015
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of somatropin, testosterone undecanoate in growth hormone deficiency (GHD), Hypogonadism, sponsored by Max Planck Institute of Psychiatry. Started Nov 2011; status: terminated.
02
Drugs
somatropintestosterone undecanoate
03
Conditions
growth hormone deficiency (GHD)Hypogonadism
Beyond the preview
Go deeper on NCT01397500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01397500.